BSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Boston Scientific is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 ready to deploy immediately. The business is still growing well, but the stock is technically weak, analyst targets have been cut broadly after guidance reset, insiders are selling, and headline litigation risk is active. If you want an immediate entry, this is a hold rather than a buy.
BSX is in a short-term bearish trend. MACD histogram is negative at -0.176, RSI_6 is 34.908 showing weak but not oversold momentum, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price at 56.31 is below the pivot level of 59.554 and only slightly above support at 55.356, which suggests limited near-term upside unless it reclaims the pivot. The pattern-based outlook also points to weakness over the next week.
["Q1 2026 revenue rose 11.58% YoY to $5.203B.", "Net income rose 98.96% YoY and EPS doubled to $0.90.", "Gross margin improved to 64.89%.", "Several analysts still keep Buy/Outperform-type ratings and see reset expectations as a possible setup for recovery.", "Argus and Barclays highlighted attractive end markets and potential upside from reset guidance and buybacks."]
["Boston Scientific is facing a class action lawsuit tied to alleged misleading statements in its U.S. Electrophysiology segment.", "Insiders are selling, and the selling amount increased sharply over the last month.", "Daiwa downgraded the stock to Neutral and cut its target materially to $60.", "Multiple firms lowered price targets after Q1 and the FY26 guidance cut.", "Technical trend remains bearish and the stock is underperforming recently."]
In Q1 2026, Boston Scientific posted strong operating growth: revenue increased 11.58% YoY to $5.203B, net income increased 98.96% YoY to $1.341B, EPS increased 100% YoY to $0.90, and gross margin improved to 64.89%. The latest quarter season is Q1 2026. The main concern is not the quarter itself, which was strong, but that management cut full-year guidance, implying slower growth ahead in WATCHMAN, U.S. EP, and Urology.
Analyst sentiment is still mixed to positive, but clearly less enthusiastic than before. Several firms kept Buy/Outperform ratings, yet price targets were cut across the board after Q1 and the guidance reset. Daiwa downgraded to Neutral with a $60 target, while others such as Argus, RBC, Oppenheimer, Truist, Nephron, Canaccord, Needham, Barclays, and Wells Fargo mostly maintained bullish ratings but reduced targets substantially. Wall Street’s bull case is that expectations are now reset, growth areas remain strong, and valuation may be more attractive. The bear case is that competitive pressure, weaker guidance, and legal/headline risk have reduced confidence in near-term upside.
